Fibroblast Growth Factor 23 and Hypertensive Disorder Complicating Pregnancy

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jan 26, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a condition called pregnancy-induced hypertension, which is when a woman experiences high blood pressure during pregnancy. This condition can be serious and affect the health of both the mother and the baby. Researchers want to understand more about a substance in the body called fibroblast growth factor 23 (FGF23) and how it might be related to the development of high blood pressure during pregnancy. They are specifically looking to see if the levels of FGF23 are different in women with pregnancy-induced hypertension compared to those with normal pregnancies.

To participate in this study, women must be between 18 and 40 years old, be having a single pregnancy, and have been attending regular check-ups since the early stages of their pregnancy. Participants will need to give birth at a specific hospital, which is the first affiliated hospital of Sun Yat-sen University. Throughout the study, participants can expect to undergo tests and evaluations to measure FGF23 levels and monitor their health. This research could help improve understanding and treatment of high blood pressure in pregnant women, ultimately benefiting maternal and infant health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with singleton pregnancy;
• • Regular antenatal examination from the first trimester;
• • Give birth in the university hospital (The 1st affiliated hospital of Sun Yat-sen University)
• Exclusion Criteria:
• • Younger than 18 years old;
• • Older than 40 years old;
• • Multiple pregnancy;
• • Complicated with other diseases such as hypertension, eclampsia, thyroid diseases, etc.